期刊文献+

透明质酸磷脂酰衍生物修饰姜黄素脂质体的制备及细胞毒性 被引量:8

Preparation and Cytotoxicity of Hyaluronic Acid Phosphatidyl Derivative Modified Curcumin Liposomes
原文传递
导出
摘要 采用逆相蒸发法制备了姜黄素脂质体。由于透明质酸脂溶性较差,先将其制成磷脂酰衍生物(透明质酸-磷脂酰乙醇胺,HA-DOPE),再用以修饰载药脂质体。所得脂质体的平均包封率为89%,该衍生物与脂质体的结合率为72%。脂质体于4℃保存30 d包封率无明显改变,但结合率有轻微下降。细胞毒性试验显示,游离姜黄素、姜黄素脂质体及修饰后脂质体对高表达CD44受体的人肺腺癌A549细胞的IC50值分别为0.054、0.032和0.021 mol/ml,未修饰和修饰后的姜黄素脂质体对低表达CD44受体的人肝癌HepG2细胞作用相当。 The curcumin liposomes were prepared by the reverse-phase evaporation method. Hyaluronic acid was first converted into its phosphatidyl derivative (HA-DOPE), which was used to modify the prepared liposomes. The average entrapment efficiency was 89 % and binding rate of HA-DOPE to liposomes was 72 %. After storing at 4 ℃ for 30 d, the entrapment efficiency of product did not change significantly, but the binding rate decreased slightly. The IC50 values were found to be 0.054, 0.032 and 0.021 μmol/ml for free curcumin, curcumin liposomes and modified curcumin liposomes, respectively after incubation with A549 cells overexpressing CD44 receptor. The unmodified and modified curcumin liposomes had similar cytotoxicity effect on HepG2 cells underexpressing CD44 receptor.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2013年第5期471-474,491,共5页 Chinese Journal of Pharmaceuticals
关键词 姜黄素 透明质酸 磷脂酰衍生物 脂质体 制备 细胞毒性 curcumin hyaluronic acid phosphatidyl derivative liposorne preparation cytotoxicity
  • 相关文献

参考文献11

  • 1许东晖,王胜,金晶,梅雪婷,许实波.姜黄素的药理作用研究进展[J].中草药,2005,36(11):1737-1740. 被引量:88
  • 2李彧,杨丽霞,李亚东,刘铜华,王继峰.姜黄素抗纤维化作用研究进展[J].北京中医药大学学报,2008,31(6):408-411. 被引量:12
  • 3Park K, Lee MY, Kim KS, et al. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate [J]. Biomaterials, 2010, 31 (19) : 5258-5265.
  • 4Naor D, Wallach-Dayan SB, Zahalka MA, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination [J]. Semin Cancer Biol, 2008, 18 (4): 260-267.
  • 5Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours [J]. Eur J Cancer, 2010, 46 (7) : 1271-1277.
  • 6Surace C, Arpicco S, Dufa:-Wojcicki A, et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells [J]. Mol Pharm, 2009, 6(4): 1062-1073.
  • 7Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells EJ]. CancerRes, 2001, 61 (6) : 2592-2601.
  • 8Taetz S, Bochot A, Surace C, et al. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti- telomerase siRNA to CD44-expressing lung cancer cells [J]. Oligonucleotides, 2009, 19 (2): 103-116.
  • 9Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic :d derivatives [J]. J Controlled Release, 2010, 141 (1) : 2-12.
  • 10Wojcicki AD, Hillaireau H, Nascimento TL, et al. Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptor [J]. J Controlled Release, 2012, 162 (3) : 545-552.

二级参考文献56

共引文献99

同被引文献116

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部